WST
West Pharmaceutical Services, Inc.
Stock
$364.98−0.03 (−0.01%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $662M | $755M | $653M | $777M | $724M | $584M | $473M | $367M | $289M | $263M | $219M | $212M | $183M | $221M | $187M | $131M | $138M | $138M | $135M |
| Capital expenditures | $225M | $286M | $377M | $362M | $285M | $253M | $174M | $126M | $105M | $131M | $170M | $132M | $112M | $152M | $131M | $95M | $71M | $105M | $139M |
| Free cash flow | $437M | $469M | $276M | $415M | $439M | $331M | $298M | $241M | $184M | $133M | $49M | $81M | $71M | $69M | $56M | $35M | $67M | $33M | −$3.6M |
| Stock-based compensation | $33M | $24M | $19M | $23M | $24M | $38M | $34M | $24M | $15M | $16M | $20M | $30M | $19M | $21M | $16M | $8.4M | $7.8M | $7.5M | $6.4M |
| Buybacks | $454M | $134M | $561M | $438M | $203M | $137M | $116M | $83M | $71M | $74M | $52M | $0 | $0 | — | $4.7M | $3.5M | $2.1M | $1.3M | $5.2M |
| Dividends paid | $62M | $61M | $59M | $57M | $54M | $51M | $48M | $45M | $42M | $39M | $36M | $32M | $29M | $27M | $25M | $23M | $22M | $20M | $19M |
| Dividends per share | — | $0.86 | $0.82 | $0.78 | $0.74 | $0.70 | $0.66 | $0.62 | $0.58 | $0.54 | $0.50 | $0.46 | $0.41 | $0.39 | $0.37 | $0.35 | $0.33 | $0.31 | $0.29 |
| Free cash flow margin | 13.1% | 15.3% | 9.6% | 14.1% | 15.2% | 11.7% | 13.9% | 13.1% | 10.7% | 8.3% | 3.3% | 5.8% | 5.0% | 5.0% | 4.4% | 3.0% | 6.1% | 3.1% | −0.3% |